Menu

New products

Daewoong Pharma is striving to develop innovative drugs that can improve global health.
We are always welcoming for a new idea in various fields and we can work together, we can work together for global drug development.

Innovative new medicines
New biologics
Incrementally modified drugs
/ specialty generics
Drug substance
  • Indications

    Gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, gastritis, etc. (Diseases in relation with gastric acid secretion)

  • Mechanism

    Gastric acid secretion is inhibited by reversible proton pump inhibitors (Potassium-competitive acid pump antagonist)

  • Development stage

    Phase 1 clinical trial is completed in Korea, and phase 2 clinical trial is underway in the United States, Australia, China, etc.

  • Scheduled date of release

    4Q, 2020

  • Partnership areas

    Differentiation from PPI products and research to meet unmet medical needs

  • Indication

    Neuropathic pain

  • Mechanism

    Pain treatment through the inhibition of Nav 1.7 sodium channel

  • Development stage

    Identification of Identification of candidate materials

  • Scheduled release date

    4Q, 2025

  • Partnership areas

    Neuropathic pain clinical indication-related basic research (in vitro, animal models included), Neuropathic pain clinical consultation

  • Indications

    Anti-fibrosis (idiopathic pulmonary fibrosis (IPF), cardiac fibrosis, liver fibrosis, and kidney fibrosis)

  • Mechanism

    Inhibition of fibrotic factors (α-SMA, Snail, and collagen) synthesis by PRS (Prolyl-tRNASynthetase) enzyme inhibition related to amino acid synthesis

  • Development stage

    Identification of Identification of candidate materials

  • Scheduled release date

    4Q, 2025

  • Partnership areas

    PRS fibrosis-related mode of action, Animal efficacy evaluation system for fibrosis diseases, Assessment model for disease extension such as NASH

  • Indication

    Rheumatoid Arthritis

  • Mechanism

    Medicines that simultaneously inhibit two targets for autoimmune disease induction

  • Development stage

    Identification of candidate materials

  • Scheduled release date

    4Q, 2025

  • Partnership areas

    Animal models related to immune diseases for expanding indications, Immune cell activation assay, Disease-relevant in vitro assay

  • Indications

    Wrinkles, upper limb muscle stiffness, etc.

  • Mechanism

    Secretion-blocking of acetylcholine which is a neurotransmitter

  • Development stage

    Released in Korea (for wrinkles and upper limb muscle stiffness), Expanding indications (Phase 3 clinical trial - wrinkles, Phase 2 clinical trial – eyelid spasm), Global market (U.S. / Europe: Preparing for product approval, China: Submitted CTA application)

  • Scheduled release date

    U.S./Europe in 2018, China in 2022

  • Partnership areas

    New indications and animal models, Development of in-vitro toxin activity measuring method to replace animal evaluation, Technology related to the development of recombinant botulinum toxin, Development of products using botulinum toxin other than Type A1.

  • Indications

    Type 1 and type 2 diabetes

  • Mechanism

    Insulin receptor agonist

  • Development stage

    Identification of candidate materials

  • Scheduled release date

    2024

  • Partnership areas

    Extended-release preparation technology, Protein stabilization technology

  • Indications

    Solid cancer, etc.

  • Mechanism

    Inhibition of the action of immunosuppressive signaling factors (immune checkpoint inhibitor)

  • Development stage

    Identification of candidate materials

  • Scheduled release date

    2027

  • Partnership areas

    Effective lead antibody and antibody target against patients who do not respond to conventional PD-1/PD-L1 antibody, Antibody screening in-vitro evaluation system, Patient screening biomarker

  • Indications

    Hypertension and dyslipidemia

  • Mechanism

    Rosuvastatin (HMG-CoA reductase inhibitor), Olmesartan (angiotensin 2 receptor antagonist)

  • Development stage

    Released in Korea

  • Scheduled release date

    U.S./Europe in 2019

  • Partnership areas

    Ideas for new combination preparation, Multiparticulate system (extended-release/enteric-coated pellets) technology

  • Indications

    Endometriosis/myoma, prostate cancer, pre-menopausal breast cancer, and central orecicuiys puberty

  • Mechanism

    Gonadotropin releasing hormone (gonadotrophin releasing hormone, GnRH) analog

  • Development stage

    Released in Korea

  • Scheduled date

    Approval in Japan/U.S. by 2020

  • Partnership areas

    Partnership for U.S./Europe joint development and technology export

  • Indications

    Prevention of nauseating·vomiting after administration of anticancer drugs

  • Mechanism

    NK 1 receptor inhibition

  • Development stage

    Manufacturing investigational drugs for overseas trials

  • Scheduled release date

    Approval in Japan/U.S. by 2020

  • Partnership areas

    Development of candidate drugs which require nanoparticle technology and products that can be applied to nano equipment, Partnership to enter into developed markets

  • Indication

    Alzheimer’s dementia

  • Mechanism

    Acetylcholinesterase inhibitor

  • Development stage

    Manufacturing for overseas trials

  • Scheduled release date

    L/O after Phase 1 clinical trial in 2019

  • Partnership areas

    cGMP CMO cooperation for patches

  • Products of interest

    UCDA/CA, choline alfoscerate

  • Development stage

    Released

  • Partnership areas
    • UDCA/CA : New manufacturing method of CA/CDCA using a variety of sources, new synthesis process for UDCA/CA
    • Choline alfoscerate : New method of extraction/separation process

New platform technology

Daewoong Pharma is always opened to partnership in various fields.
Please take a look at the following areas for cooperation and propose your platform technologies.

Ion channel platform
  • Progress status
    • Identification of candidate materials for Nav1.7 innovative pain medicine
  • Core competencies of Daewoong Pharma
    • Ion cannel evaluation technology
    • Ion channel high-through put evaluation method, patch clamp equipment/technology
    • Ion channel focused chemical libraries and 100,000 in-house compounds (TRPV1, Nav1.7 target)
    • In-vivo animal model based assessment for Neuropathic pain disorders
  • Partnership areas
    • New ion channel targets and disease studies
    • Primary cell, ex-vivo evaluation technology, ion channel established cell technology
Stem cell platform
  • Progress status
    • Clinical studies : Atopy, Cronhn’s disease, and rheumatoid arthritis
    • Investigator initiated clinical : Cerebellar atrophy, vesicular epidermolysis, and acute severe pancreatitisc
    • Efficacy evaluation in animal study : Dementia, degenerative arthritis, liver disease, and stroke
  • Core competencies of Daewoong Pharma
    • Two types of mesenchymal stem cells (ES-MSC, UCB-MSC), growth factors (EGF,EPO,hGH,BMP-2)
    • Cell treatment GMP facilities : Research facilities for evaluating and enhancing efficacy of stem cells (open to partners)
    • Systematic system for stem cell research : Latest papers and development trend information, statistical analysis
    • preparation of thesis and IRB review research plan, and IND application related affairs
  • Partnership areas
    • Finding new efficacy of stem cells, expansion of indications, stem cell efficacy enhancement technology, and mass culture technology
Escherichia coli based platform
  • Progress status
    • EGF, EPO, hGH (Growth hormone), BMP-2 products are released
    • Identification of insulin bio-better candidate materials
  • Core competencies of Daewoong Pharma
    • Activation technology and expertise suitable for the characteristics of various types of protein : Refolding, active type, secretory type, etc.
    • Approval/commercialization/production capability of Escherichia coli-based biologics : Commercialization capability of Escherichia coli-based biologics such as EGF, BMP-2, hGH, EPO
  • Partnership areas
    • Protein extended-release preparation technology, new protein drugs using new MOA (mode of action), and metabolic engineering technology to increase the production of recombinant protein
    • Protein skin permeation technology, protein room temperature stabilization technology
Depot technology platform
  • Progress
    • Long-term release anticancer drug : Nonclinical study / Nano path type dementia treatment : Clinical study / Leuprolide depot’s entry into the US market : Clinical study / Sustained-release antithrombotic preparation : Formulation study / - Long-term release dementia treatment : Formulation study
  • Core competencies of Daewoong Pharma
    • Depot injection based technology : Microsphere technology (spray type, emulsion type, nano suspension), Sustained-release preparation technology such as nano suspension technology which is applicable to poorly soluble drugs
    • Animal/preliminary clinical system capable of speedy POC evaluation
    • Luphere manufacturing competitiveness : Building Leuprolide depot cGMP plant, Dual-chamber syringe technology
  • Partnership areas
    • New substance to which depot injection technology can be applied
    • Sustained-release preparation platform technology
    • Product manufacturing CDMO (Contract Development and Manufacturing Organization)
Drug substance (API) production platform
  • Core competencies of Daewoong Pharma
    • Possession of advanced research system and special facilities : cGMP quality management system, facilities and equipment infrastructure
    • API manufacturing synthesis competitiveness and know-how : Developed and exported products such as valsartan, meropenem, lansoprazole, rabeprazole, and choline alfoscerate based on UDCA R&D and industrialization technology experience to developed countries
  • Partnership areas
    • Production of CA/CDCA using various sources, improvement of UDCA synthesis process
    • CDMO partnership
next previous